Preclinical evidence construction for epigallocatechin-3-gallate against non-alcoholic fatty liver disease: a meta-analysis and machine learning study.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published Date: Apr 10, 2025

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has emerged as a significant health concern worldwide, exhibiting an increasing incidence that necessitates immediate intervention. Epigallocatechin-3-gallate (EGCG) has shown significant pharmacological benefits for liver diseases, including NAFLD. However, its efficacy in this context has not been systematically evaluated.

Authors

  • Yuanhao Zhang
    Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China; TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China; School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
  • Jianguo Li
    The Key Lab of Health Chemistry & Molecular Diagnosis of Suzhou, College of Chemistry, Chemical Engineering & Materials Science, Soochow University, Renai Road 199, Suzhou 215123, China. Electronic address: lijgsd@suda.edu.cn.
  • Zexin Wang
  • Jie Chen
    School of Basic Medical Sciences, Health Science Center, Ningbo University, Ningbo, China.
  • Maoyuan Zhao
    School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, China.
  • Cui Guo
    School of Computer, Shenyang Aerospace University, Shenyang, China.
  • Tingyao Wang
    School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
  • Ruilin Li
    Computer Network Information Center, Chinese Academy of Sciences, Beijing 100190, China.
  • Hebin Zhang
    School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, 610075, China.
  • Xiao Ma
    Department of Ultrasound, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Yueqiang Wen
    School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: wenyueqiang@cdutcm.edu.cn.
  • Jinhao Zeng
    TCM Regulating Metabolic Diseases Key Laboratory of Sichuan Province, Department of Gastroenterology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China. Electronic address: zengjinhao@cdutcm.edu.cn.
  • Thomas Efferth
    Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University Mainz, Germany.

Keywords

External Resources

Popular Topics
Recent Journals